目的 觀察龍金通淋膠囊聯(lián)合環(huán)丙沙星片治療慢性前列腺炎的臨床療效。方法 選取赤峰市腫瘤醫(yī)院于2022年6月—2023年12月收治的140例慢性前列腺炎患者作為研究對象，按照隨機(jī)數(shù)字表法將患者分為對照組和治療組，各為70例。對照組飯前或飯后口服環(huán)丙沙星片，1片/次，早晚各1次。治療組在對照組用藥基礎(chǔ)上口服龍金通淋膠囊，2～3粒/次，3次/d。兩組均治療1個月。對比兩組臨床療效、臨床癥狀、尿動力學(xué)指標(biāo)、血清炎癥指標(biāo)。結(jié)果 治療組的總有效率為90.00%，高于對照組的總有效率74.29%（P＜0.05）。治療后，兩組美國國立衛(wèi)生研究院慢性前列腺炎癥狀指數(shù)（NIH-CPSI）評分、膀胱殘余尿量（PVR）、最大逼尿肌壓力、血清腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-8（IL-8）、白細(xì)胞介素-17（IL-17）水平均下降，最大尿流率（Q_max）升高（P＜0.05），治療組的各指標(biāo)優(yōu)于對照組（P＜0.05）。結(jié)論 龍金通淋膠囊聯(lián)合環(huán)丙沙星片治療慢性前列腺炎可有效改善患者臨床癥狀和尿動力學(xué)指標(biāo)，降低炎癥因子水平。

Objective To observe the clinical study of Longjin Tonglin Capsules combined with Ciprofloxacin Tablets in treatment of chronic prostatitis. Methods 140 Patients with chronic prostatitis in Chifeng Cancer Hospital from June 2022 to December 2023 were divided into control group and treatment group according to the random number table method, with 70 cases in each group. Patients in the control group po administered with Ciprofloxacin Tablets before or after meals, 1 tablets per time, once in the morning and once in the evening. On the basis of the control group, patients in the control group po administered with Longjin Tonglin Capsules, 2 — 3 capsules/time, 3 times daily. Both groups were treated for one month. The clinical efficacy, clinical symptoms, urodynamic indicators, and serum inflammatory indicators between two groups were compared. Results The total effective rate of the treatment group was 90.00%, which was higher than74.29% of the control group (P < 0.05). After treatment, NIH-CPSI score, PVR, maximum detrusor pressure, serum levels of TNF-α, IL-8, and IL-17 in two groups were decreased, while Q_max was increased (P < 0.05). The above indicators in the treatment group were better than those in the control group (P < 0.05). Conclusion Longjin Tonglin Capsules combined with Ciprofloxacin Tablets can effectively improve the clinical symptoms and urodynamic indicators of patients with chronic prostatitis, and reduce the levels of inflammatory factors.

R983

內(nèi)蒙古自治區(qū)衛(wèi)生健康科技計劃項目(202201555)